Dr. Peter A. Ljubenkov, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Temple University School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 85
Licensed in California since 2013, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Temple University School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A124893 (first issued 2013; current) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 85
- Services billed
- 155
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 75 | 28 |
| Established patient office or other outpatient visit, 40-54 minutes | 50 | 46 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 14 | 14 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | 12 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in San Francisco, CA | 48 |
| Escitalopram Oxalate Other prescribers in San Francisco, CA | 28 |
| Rivastigmine Other prescribers in San Francisco, CA | 27 |
| Memantine Hcl Other prescribers in San Francisco, CA | 23 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in San Francisco, CA | 20 |
| Trazodone Hcl Other prescribers in San Francisco, CA | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $354,065 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (Targe…
E.r. Squibb & Sons, L.l.c. - A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
AbbVie Inc. · Completed · NCT02880956 - An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)
AbbVie Inc. · Terminated · NCT03712787
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.